91 related articles for article (PubMed ID: 16857818)
1. Epidermal growth factor receptor mutation testing in the care of lung cancer patients.
Sequist LV; Joshi VA; Jänne PA; Bell DW; Fidias P; Lindeman NI; Louis DN; Lee JC; Mark EJ; Longtine J; Verlander P; Kucherlapati R; Meyerson M; Haber DA; Johnson BE; Lynch TJ
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4403s-4408s. PubMed ID: 16857818
[TBL] [Abstract][Full Text] [Related]
2. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.
Kancha RK; von Bubnoff N; Peschel C; Duyster J
Clin Cancer Res; 2009 Jan; 15(2):460-7. PubMed ID: 19147750
[TBL] [Abstract][Full Text] [Related]
3. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Jänne PA; Johnson BE
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
[TBL] [Abstract][Full Text] [Related]
4. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis.
Kawahara A; Yamamoto C; Nakashima K; Azuma K; Hattori S; Kashihara M; Aizawa H; Basaki Y; Kuwano M; Kage M; Mitsudomi T; Ono M
Clin Cancer Res; 2010 Jun; 16(12):3163-70. PubMed ID: 20423982
[TBL] [Abstract][Full Text] [Related]
5. Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis.
Smith GD; Chadwick BE; Willmore-Payne C; Bentz JS
J Clin Pathol; 2008 Apr; 61(4):487-93. PubMed ID: 17908804
[TBL] [Abstract][Full Text] [Related]
6. Impact of EGFR mutation analysis in non-small cell lung cancer.
Yamamoto H; Toyooka S; Mitsudomi T
Lung Cancer; 2009 Mar; 63(3):315-21. PubMed ID: 18760859
[TBL] [Abstract][Full Text] [Related]
7. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
[TBL] [Abstract][Full Text] [Related]
8. Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis.
Nomoto K; Tsuta K; Takano T; Fukui T; Fukui T; Yokozawa K; Sakamoto H; Yoshida T; Maeshima AM; Shibata T; Furuta K; Ohe Y; Matsuno Y
Am J Clin Pathol; 2006 Oct; 126(4):608-15. PubMed ID: 16938658
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer.
Cohen V; Agulnik JS; Jarry J; Batist G; Small D; Kreisman H; Tejada NA; Miller WH; Chong G
Cancer; 2006 Dec; 107(12):2858-65. PubMed ID: 17096434
[TBL] [Abstract][Full Text] [Related]
10. Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer.
Fukui T; Ohe Y; Tsuta K; Furuta K; Sakamoto H; Takano T; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Asamura H; Tsuchida T; Kaneko M; Kusumoto M; Yamamoto S; Yoshida T; Tamura T
Clin Cancer Res; 2008 Aug; 14(15):4751-7. PubMed ID: 18676744
[TBL] [Abstract][Full Text] [Related]
11. Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer.
Sonobe M; Nakagawa M; Takenaka K; Katakura H; Adachi M; Yanagihara K; Otake Y; Wada H; Tanaka F
J Surg Oncol; 2007 Jan; 95(1):63-9. PubMed ID: 17192868
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor mutations in small cell lung cancer.
Tatematsu A; Shimizu J; Murakami Y; Horio Y; Nakamura S; Hida T; Mitsudomi T; Yatabe Y
Clin Cancer Res; 2008 Oct; 14(19):6092-6. PubMed ID: 18829487
[TBL] [Abstract][Full Text] [Related]
13. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
[TBL] [Abstract][Full Text] [Related]
14. The survival outcomes of patients with resected non-small cell lung cancer differ according to EGFR mutations and the P21 expression.
Na II; Rho JK; Choi YJ; Kim CH; Park JH; Koh JS; Ryoo BY; Yang SH; Lee JC
Lung Cancer; 2007 Jul; 57(1):96-102. PubMed ID: 17337084
[TBL] [Abstract][Full Text] [Related]
15. Simple polymerase chain reaction for the detection of mutations and deletions in the epidermal growth factor receptor gene: applications of this method for the diagnosis of non-small-cell lung cancer.
Uhara M; Matsuda K; Taira C; Higuchi Y; Okumura N; Yamauchi K
Clin Chim Acta; 2009 Mar; 401(1-2):68-72. PubMed ID: 19063875
[TBL] [Abstract][Full Text] [Related]
16. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
John T; Liu G; Tsao MS
Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
[TBL] [Abstract][Full Text] [Related]
17. Cytomorphological correlates of epidermal growth factor receptor mutations in lung carcinoma.
Brachtel EF; Iafrate AJ; Mark EJ; Deshpande V
Diagn Cytopathol; 2007 May; 35(5):257-62. PubMed ID: 17427221
[TBL] [Abstract][Full Text] [Related]
18. Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay.
Asano H; Toyooka S; Tokumo M; Ichimura K; Aoe K; Ito S; Tsukuda K; Ouchida M; Aoe M; Katayama H; Hiraki A; Sugi K; Kiura K; Date H; Shimizu N
Clin Cancer Res; 2006 Jan; 12(1):43-8. PubMed ID: 16397022
[TBL] [Abstract][Full Text] [Related]
19. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status.
Pesek M; Benesova L; Belsanova B; Mukensnabl P; Bruha F; Minarik M
Anticancer Res; 2009 Jul; 29(7):2767-73. PubMed ID: 19596959
[TBL] [Abstract][Full Text] [Related]
20. A useful protocol for analyses of mutations of the epidermal growth factor receptor gene.
Liu D; Nakano J; Ueno M; Masuya D; Nakashima T; Yokomise H; Yube K; Huang CL
Oncol Rep; 2006 Jun; 15(6):1503-5. PubMed ID: 16685386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
